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Description
FIELD OF THE INVENTION
[0001] This invention relates to the use of glycosides of mono- or diacylglycerol, e.g. 3-β-D-galactopyranosyloxy-
2-(octadeca-9Z,12Z,15Z-trienoyloxy)propanyl octadeca-9Z,12Z,15Z-trienoate (a constituent of rose-hips (the fruits of
Rosa canina L.)), for the preparation of a medicament for the treatment of inflammatory conditions, e.g. treatment of
inflammation by alleviating chemotaxis and oxidative burst response of leukocytes.
BACKGROUND OF THE INVENTION
[0002] The anti-inflammatory properties of water-extracts of rose-hips have previously been reported (Winther, Rein,
and Kharazmi, Inflammopharmacology, Vol. 7, pp 63-68 (1999)). Extracts of rose-hips are also known to inhibit chemotaxis
and chemiluminescence of human peripheral blood neutrophils in vitro and to reduce certain inflammatory parameters
in vivo (Kharazmi and Winther, Inflammopharmacology, Vol.7, pp 377-386 (1999)).
[0003] In U.S. Patent No. 6,024,960, a rose-hip concentrate having a high content of vitamin C was found to alleviate
the symptoms associated with inflammation. Specifically, the concentrate was obtained in accordance with a process
that preserved a relatively high vitamin C content as well as the content of a number of other vitamins. In the applicants’
related U.S. patent Application No. 09/694,764, filed on October 23, 2000, the oral administration of a combination of a
rose-hip concentrate and fish oil is described as being useful in the alleviation of joint pain and stiffness, particularly in
relation to arthritis. However, the quantity of rose-hip concentrate described in each of these applications as being useful
to obtain a beneficial effect was relatively high and somewhat inconvenient for daily usage.
[0004] In U.S. Patent Nos. 5,620,962 and 5,767,095, monogalactosyl dieicosapentaenoyl glycerol (MGDG-EPA) ob-
tained from marine algae was described as having anti-inflammatory properties when used in a topical formulation.
These patents describe that only galactosyl glycerols esterified with at least one eicosapentaenoic acids moiety possess
topical anti-inflammatory properties.
[0005] β-D-Galactopyranosylglycerols esterified with a 1:10:10 mixture of myristic, palmitic and palmotoleic acid were
claimed modestly to inhibit superoxide radical formation (Kikuchi, H., Tsukitani, Y., Shimizu, I., Kobayashi, M., Kitagawa,
J: Chem. Pharm. Bull. Vol. 31 pp  552 - 556 (1983)), but no further investigations of the anti-inflammatory properties of
this mixture of compounds and of the potential medical uses have been performed.
Otha, Naoki et al: "Synthesis of biologically active galactosyl...", Vol. 39. No. 5, (1991) discloses compounds exhibiting
anti-inflammatory activity in general and no special inflammatory condition is been described.
Murakami, Akira et al: "Glyceroglycolipids from.." J. aaAgric Food Chem, Vol 43, 2779-2783, (1995) discloses compounds
isolated from the Euphorbia cyparissias. The compounds are used for cancer chemoprevention or as an anti-tumor
promoter and have shown anti-inflammatory activity on a mouse ear in the same manner as disclosed by Cateni et
al.XP-002237421, Database STN Caplus, "Galactolipids from Mori Folium...", Vol. 31. No. 1, (2000) discloses galactolipid
compounds isolated from Morus alba used for the treatment of cancer.
Cateni F et al., "Biologically active compounds...", Pharm Pharmacol Lett, Vol. 2, (2001) discloses compounds isolated
from the leaves of Citrus hysterix which are similar to the compound(s) disclosed by the present invention. The compounds
antagonize TPA induced skin irritation and Epstein Barr virus activation. It is suggested that the compounds inhibit the
arachidonic acid cascade.
WO 98/30573 and EP 0 671 406 disclose anti-adhesive sulfonylated compounds having anti-inflammatory activity for
conditions such as rheumatoid arthritis and osteoarthritis. Neither WO 98/30573 nor EP 0 671 406 discloses non-
sulfonylated glycolipid compounds. Ohta et al. (Chem. Pharm. Bull. 39(5), 1337-9), Murakami et al. (J. Agric. Food Chem.
1995, 43, 2779-83), Kim et al (Saengyak Hakhoechi 2000, 31(1), 95-100), Cateni et al. (Pharm. Pharmacol Lett., 2001,
2, 53-57), WO9830573 and EP0671406 all disclose glycolipid derivating having various biological activities such as anti-
inflammatory, anti-diabetic or anti-adhesion properties.
SUMMARY OF THE INVENTION
[0006] In the applicants’ continuing studies of concentrates of rose-hips, the applicants have surprisingly discovered
that a particular constituent of rose-hips is a highly active anti-inflammatory agent. Since rose-hips taken orally efficiently
alleviate inflammatory pains such as the pain associated with arthritis, a formulation of the identified anti-inflammatory
agent is believed to be useful for the treatment of symptoms associated with inflammatory diseases. The isolated
substance was identified as the galactolipid 3-β-D-galactopyranosyl-oxy-2-(octadeca-9Z,12Z,15Z-trienoyloxy)propanyl
octadeca-9Z,12Z,15Z-trienoate (1,2-di-O-α-linolenoyl-3-O-β-D-galactopyranosyl-glycerol), as will be described further
below.
Surprisingly, this compound was found to potently inhibit chemotaxis as well as chemiluminescence of polymorphonuclear
EP 1 453 844 B1
4
5
10
15
20
25
30
35
40
45
50
55
leukocytes.
[0007] It is thus an object of the present invention to use glycosides of mono- or diesters of glycerol with the exception
of esters of eicosapentaenoic acid, and especially of 3-β-D-galactopyranosyloxy-2-(octadeca-9Z,12Z,15Z-trienoyloxy)
propanyl octadeca-9Z,12Z,15Z-trienoate (in short, "GOPO") or related compounds for the preparation of a medicament
for the treatment of an inflammatory condition selected from rheumatoid arthritis, inflammatory bowel diseases, reactive
or osteo-arthristis or other arthritides. In a particular aspect of the invention, the medicament is adapted for oral use and
for alleviating the symptoms of inflammatory diseases, such as arthritis and osteoarthrosis (i.e. diseases causing joint
pains or joint stiffness) including relief of pain, reduction of inflammation and increase of motion.
[0008] This and other objects of the present invention are achieved by glycosides of mono- or diesters (or ethers) of
glycerol with the exception of esters of eicosapentaenoic acid, in particular as defined in claim 1.
BRIEF DESCRIPTION OF THE DRAWINGS
[0009]
Figure 1 illustrates the first step of the fractionation process originally used in order to isolate the anti-inflammatory
agent from rose-hips of Rosa canina L.
Figure 2 shows a typical analytical HPLC chromatogram of a THF extract from dried and milled peels of dog rose
fruits (Rosa canina L.) obtained from Hyben Vital International ApS. Furthermore the retention time of the active
compound (GOPO) is indicated.
DETAILED DESCRIPTION OF THE INVENTION
[0010] The terms "glycoside of a mono- or diesterified glycerol", "glycosides of mono- or diacylglycerol" and similar
terms are intended to mean a class of glycosides of mono- or diacylglycerols (as well as ethers), such as those which
can be isolated from plants as illustrated by the various formulas herein, and which are not esters of eicosapentaenoic
acid. The "glycoside" part is typically a pentose, hexose or heptose, in particular hexoses such as galactose and glucose,
e.g. galactose, but can also be di- and oligosaccharides containing two or more sugar moieties in combination, in
particular diglycosides such as digalactosides and diglucosides, e.g. 6-O-(α-D-galactopyranosyl)-β-D-galactopyranose.
[0011] Thus, the present invention provides the use of a compound of the formula I: 
wherein R and R’ independently are selected from hydrogen, C10-24-alkyl, and C10-24-acyl, said alkyl and acyl groups
having 0 to 5 unsaturated bonds, and R1, R2, R3 and R4 independently are selected from hydrogen and glycoside
moieties; with the first proviso that not both of R and R’ are hydrogen, and with the second proviso that none of R and
R’ is eicosapentaenoyl, for the preparation of a medicament for the treatment, alleviation or prophylaxis of inflammatory
condition selected from rheumatoid arthritis, inflammatory bowel diseases, reactive or osteo-arthritis or other arthritides
in a mammal.
[0012] The "wavy bonds" in the formulae presented herein are intended to mean that the carbon on which the substituent
in question is positioned may be in the (R) or (S) configuration. In the "sugar" moiety (glycoside) the two different
configurations are some times designated a and β. A particular interesting combination is glucose or galactose in the β-
pyranose form.
[0013] Although the "sugar" moiety in the formulae presented herein is drawn in the pyranose form, it will be understood
that the anti-inflammatory agent may also be present in the furanose form (or a mixture of the pyranose and furanose
forms) as a solid and in solution. In the present context, the term "C10-24-alkyl" is intended to mean a linear or branched
hydrocarbon group having 10 to 24 carbon atoms, e.g., decyl, undecyl, dodecyl, tetradecyl, hexadecyl, octadecyl, non-
adecyl, eicodecyl, etc.
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[0014] In the present context, the term "C10-24-acyl" is intended to mean a linear or branched hydrocarbon group
having 10 to 24 carbon atoms wherein the first carbon of the group is a carbonyl (C9-23-alkyl-C(=O)-), i.e. a fatty acid
residue having 10 to 24 carbon atoms. Examples hereof are the residues of lauric acid (C12), myristic acid (C14), palmitic
acid (C16), stearic acid (C18), etc.
[0015] The alkyl and acyl groups may have 0 to 5 unsaturated bonds such as double or triple bonds, in particular
double bonds. Examples of acyl groups having one or more unsaturated double bonds are the residues of palitoleic acid
(C16:1), oleic acid (C18:1), linoleic acid (C18:2), linolenic acid (C18:3), arachidonic acid (C20:3), retinoic acid (C20:5), etc.
[0016] More specifically, the glycosides of mono- or diesters (or ethers) of glycerol are diesters, diethers, or monoether-
monoesters, i.e. R and R’ are independently selected from C10-24-alkyl and C10-24-acyl. The currently most preferred
are glycosides of diesters, i.e. R and R’ are independently C10-24-acyl. In all instances, the alkyl and acyl groups have
0 to 5 unsaturated bonds.
[0017] With respect to the degree of saturation of the alkyl and acyl groups, it is currently believed that any alkyl and
acyl groups having 0 to 4 unsaturated bonds, such as 1-3 unsaturated bonds, e.g. 2 or 3 unsaturated bonds, in particular
3 unsaturated bonds, are the most suitable as R and R’.
[0018] Also, it is currently believed that any unsaturated bonds preferably are double bonds.
[0019] This being said, it is envisaged that particularly interesting anti-inflammatory agents are those where R and R’
both are C16-20-acyl having 1 to 3 double bonds, such as C18-acyl having 3 double bonds, in particular where the "sugar"
moiety is glucose or galactose, in particular galactose.
[0020] As mentioned above, R1, R2, R3 and R4 are independently selected from hydrogen and glycoside moieties,
preferably only at the most one of R1, R2, R3 and R4 is a glycoside moiety. The latter embodiment relates to compounds
that are often found in vegetable sources along with compounds where all of R1, R2, R3 and R4 are hydrogen. In some
interesting embodiments, all of R1, R2, R3 and R4 are selected hydrogen.
[0021] The term "glycoside moieties" is intended to mean a mono- or disaccharide moiety, e.g. derived from O-
galactopyranose, O-glucopyranose, O-galactopyranosylgalactopyranose, O-glucopyranosylgalactopyranose, O-galact-
opyranosylglucopyranose and O-glucopyranosyl-glucopyranose.
[0022] Also, it is envisaged that the compound (anti-inflammatory agent) preferably has the formula II: 
wherein R, R’, R1, R2, R3 and R4 all are as defined above.
[0023] More specific examples of anti-inflammatory of particular interest are those selected from β-D-galactopyranosyl
derivatives, α-D-galactopyranosyl derivatives, β-D-glucopyranosyl derivatives, and α-D-glucopyranosyl derivatives, such
as β-D-galactopyranosyl and 6-O-(α-D-galactopyranosyl)-β-D-galactopyranosyl derivatives.
[0024] Even more specific examples of anti-inflammatory agents of interest are 3-β-D-gatactopyranosyloxy-2-(octa-
deca-9Z,12Z,15Z-trienoyloxy)propanyl octadeca-9Z,12Z,15Z-trienoate, 3-β-D-glucopyranosyloxy-2-(octadeca-9Z,12Z,
15Z-trienoyloxy)propanyl octadeca-9Z,12Z,15Z-trienoate, 3-α-D-galactopyranosyloxy-2-(octadeca-9Z,12Z,15Z-
trienoyloxy)propanyl octadeca-9Z,12Z,15Z-trienoate, 3-α-D-glucopyranosyloxy-2-(octadeca-9Z,12Z,15Z-trienoyloxy)
propanyl octadeca-9Z,12Z,15Z-trienoate, 6-O-(α-D-galactopyranosyl)-3-β-D-galactopyranosyloxy-2-(octadeca-9Z,12Z,
15Z-trienoyloxy)-propanyl octadeca-9Z,12Z,15Z-trienoate and 6-O-(α-D-galactopyranosyl)-3-α-D-galactopyranosyloxy-
2-(octadeca-9Z,12Z,15Z-trienoyloxy)propanyl octadeca-9Z,12Z,15Z-trienoate, such as 3-β-D-galactopyranosyloxy-
2-(octadeca-9Z,12Z,15Z-trienoyloxy)-propanyl octadeca-9Z,12Z,15Z-trienoate or 3-β-D-glucopyranosyloxy-
2-(octadeca9Z,12Z,15Z-trienoyloxy)propanyl octadeca-9Z,12Z,15Z-trienoate, e.g. 3-β-D-galactopyranosyloxy-2-(octa-
deca-9Z,12Z,15Z-trienoyloxy)propanyl octadeca-9Z,12Z,15Z-trienoate which can be isolated from rose-hips.
[0025] As already mentioned above, the anti-inflammatory agent may be prepared by total or partial synthesis according
to the methods known in the art (see, e.g., Nagatsu et al., Bioorg. and Medicinal Chem. Vol. 4, 1619-1622, 1994; Ohta
et al., Chem. Pharm., Vol 39, 1337-1339, 1991; Shibuya et al. Chem. Pharm., Vol. 40, 1166-1169, 1992), or the anti-
inflammatory agent may be isolated from rose-hips or other vegetative sources. Alternatively, the anti-inflammatory
agent may be present in a plant extract or material, preferably a plant extract or material enriched or standardised with
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respect to the anti-inflammatory agent.
[0026] When isolated from rose-hips, the rose-hips are harvested in a generally known manner when the hips are fully
ripe. Hips from wild rose bushes, such as Rosa canina ("dog rose-hip"), Rosa gallica, Rosa condita, Rosa rugosa, Rosa
hugonis, Rosa nitida, Rosa pendulina, Rosa pimpinellifolia, and Rosa sericea may advantageously be used. The anti-
inflammatory agent is preferably obtained by extraction from dried and milled rose-hips through solvent extraction, using
organic or inorganic solvents such as hexane, dichloromethane, ethanol, or water, though others may be used. After
extraction, the obtained extract is evaporated to dryness, to recover an extract fraction containing the anti-inflammatory
agent, or, depending on the extraction steps, the anti-inflammatory agent itself is obtained as an isolate, as will be
discussed further below.
[0027] As an example, 3-β-D-galactopyranosyloxy-2-(octadeca-9Z,12Z,15Z-trienoyloxy)propanyl octadeca-9Z,12Z,
15Z-trienoate (Formula III) was isolated from dried powder of dog-rose hip. The isolated compound not only potently
inhibits oxidative burst response but do also inhibit chemotaxis of human leukocytes. 
[0028] While an isolated compound may be used, an enriched or standardised plant extract or standardised plant
material obtained in the process of complete isolation may also be useful in the present invention, particularly as the
extracted or standardised product may be obtained at lower cost than the isolated compounds. In addition, other ingre-
dients in the extract or plant material may support or enhance the effects of the anti-inflammatory  agent, such as the
vitamins (some of which may have an anti-oxidative effect) that remain after partial extraction. The choice of whether to
treat inflammation with an enriched or standardised extract or standardised plant material as opposed to an isolated or
synthesised product most likely will depend on the extent of the inflammatory disease. For example, with arthritis, those
suffering minor discomfort would most likely be well served by administration of the enriched or standardised extract or
standardised plant material, while those more seriously debilitated may seek to use the isolated or synthesised compound.
[0029] The inventors’ observation that the compound of formula III compounds described herein inhibit the oxidative
burst response as well as chemotaxis makes it reasonably to believe that it is an active contributor to the anti-inflammatory
effect of the dried rose-hip powder. Thus, the inventors believe that this finding renders it probable that the anti-inflam-
matory agents described herein, either as isolated compounds or included in enriched or standardised extracts or
enriched plant material, are suitable for the treatment of inflammatory conditions, e.g. those associated with arthritis.
[0030] A medicament (pharmaceutical composition) comprising the anti-inflammatory agent may be useful in the
prevention, treatment or alleviation inflammation, whether caused by illness or medical conditions, such as viral or
bacterial diseases (commonly termed "inflammatory conditions"). "Inflammation" is defined in Stedman’s Medical Dic-
tionary, 26th Edition as "a fundamental pathologic process consisting of a dynamic complex of cytological and chemical
reactions that occur in the affected blood vessels and adjacent tissue in response to injury or abnormal stimulation
caused by physical, chemical or biological agent, including the local reactions and resulting morphologic changes, the
destruction of removal of the injurious material, and the responses that lead to repair and healing". Examples of relevant
inflammatory conditions are rheumatoid arthritis, inflammatory bowl diseases such as Crohn’s disease, reactive or osteo-
arthritis or other arthritides such as osteoarthrosis, multiple sclerosis, atherosclerosis, sepsis/septic shock, dermal in-
flammation, graft rejection, and inflammation secondary to chemotherapy or radiotherapy of neoplastic disease.
[0031] The present invention is presently believed to be particularly suitable for the preparation of a medicament for
the treatment of arthritis and osteoarthrosis.
Formulation
[0032] As mentioned above, the anti-inflammatory agent may be used directly as the pure compounds or as a con-
stituent of an enriched or standardised plant extract or a standardised dried plant material.
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[0033] Thus, the medicament may be in the form of an extract of a plant material, typically an extract where the
concentration of the anti-inflammatory agent is known to the extent that the dose given to the mammal can be controlled.
[0034] Regardless of form, but in particular when the compound is in the form of a pure compound, it is normally
necessary to formulate the compound so as to ease the application thereof to the mammal in need therefor, an so as
to ensure suitable bioavailability of the compound.
[0035] The anti-inflammatory agents are preferably formulated in a pharmaceutically acceptable carrier (or excipient),
optionally in combination with an anti-oxidant. They may also be combined with other active ingredients to synergise
the anti-inflammatory effects or to offer other supplemental benefits to the user.
[0036] Thus, the anti-inflammatory agent or an enriched or standardised extract or a standardised plant material
containing the anti-inflammatory agent may be formulated alone or with other ingredients, as powders, granules, tablets,
suspensions, solutions or emulsions and containing ingredients known in the art for preparing such formulation and be
packaged in single or multiple daily dose forms.
[0037] In particular, a pharmaceutical composition (medicament) typically comprises from about 0.1 to about 50% by
weight of the anti-inflammatory agent in a pharmaceutically acceptable carrier, preferably in combination with an anti-
oxidant.
[0038] Administration may proceed by oral, buccal, parenteral, topical, rectal, transdermal or intranasal administration,
though oral administration is preferred.
[0039] "Pharmaceutically acceptable carriers" as used herein are those media generally acceptable for use in con-
nection with the administration of to mammals, including humans.
[0040] The term "mammal" is intended to include larger mammals such as humans as well as domestic or farm animals
such as horses, dogs, sheep, pigs, cows, etc. Among these mammals, humans are particularly interesting subjects to
benefit form the invention.
[0041] Pharmaceutical compositions are generally formulated according to a number of factors well within the purview
of the ordinarily skilled artisan to determine and account for, including without limitation: the particular anti-inflammatory
agent, its concentration, stability and intended bioavailability; the specific inflammatory disease, disorder or condition
(collectively: "condition") being treated with the medicament; the subject, its age, size and general condition; and the
composition’s intended route of administration, e.g., oral, buccal, parenteral, topical, rectal, transdermal or internasal
administration. Typical pharmaceutically acceptable carriers used in parenteral drug administration include, for example,
D5W, an aqueous solution containing 5% weight by volume of dextrose, and physiological saline. Pharmaceutically
acceptable carriers can contain additional ingredients, for example those that enhance the stability of the active ingredients
included, such as preservatives and anti-oxidants.
[0042] In one embodiment, the medicament comprises an anti-oxidant in combination with the compound defined
herein and the pharmaceutically acceptable carrier. The anti-oxidant is, e.g., an anti-oxidant selected from Vitamin C
and derivatives thereof, Vitamin E, flavonoides, phenolic acids such as methyl, ethyl or n-propyl p-hydroxybenzoate,
carotenes, butylated hydroxyanisoles, butylated hydroxytoluenes, nordihydrogualaretic acid, etc. This embodiment is
particularly relevant where the anti-inflammatory agent comprises one or more unsaturated bonds such as double bonds,
which might make the compound susceptible to oxidative degradation.
[0043] The pharmaceutical composition may be administered parenterally by injection, infusion or implantation (intra-
venous, intramuscular, intraarticular, subcutaneous or the like) in dosage forms, formulations or e.g. suitable delivery
devices or implants containing conventional, non-toxic pharmaceutically acceptable carriers and adjuvants.
[0044] The formulation and preparation of such compositions is well-known to those skilled in the art of pharmaceutical
formulation. Specific formulations can be found in Remington: The Science and Practice of Pharmacy by Alfonso R.
Gennaro (Editor), 20th edition (2000), Lippincott, Williams & Wilkins; ISBN: 0683306472.
[0045] The anti-inflammatory agent is typically formulated in a pharmaceutically acceptable aqueous medium.
[0046] Thus, the pharmaceutical compositions may comprise the anti-inflammatory agent in the form of a sterile
injection. To prepare such a composition, the suitable anti-inflammatory agent is dispersed in a parenterally acceptable
liquid vehicle which conveniently may comprise suspending, solubilising, stabilising, pH-adjusting agents and/or dis-
persing agents. Among acceptable vehicles that may be employed are water, water adjusted to a suitable pH by addition
of an appropriate amount of hydrochloric acid, sodium hydroxide or a suitable buffer, 1,3-butanediol, Ringer’s solution
and isotonic sodium chloride solution.
[0047] The anti-inflammatory agent can be formulated for delivery via various routes of administration. Oral adminis-
tration is preferred for ease of use. A unit dosage can comprise a therapeutically effective amount of the anti-inflammatory
agent for a single daily administration (e.g. orally or by feeding tube in an enteral diet for example), or be formulated to
provide multiple doses per day. A unit dosage will depend on many factors including age, condition, and disease state,
but in any event, the entire daily dosage will be that which is physiologically acceptable to the individual and can be
administered daily over a prolonged period of time.
[0048] While still under investigation, it is believed that a dosage of from 0.001-50 mg/kg body weight per day, such
as 0.005-20 mg/kg body weight per day (mg/kg/day), of the anti-inflammatory agent, would be effective in the treatment
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of the inflammatory condition, in particular arthritis and osteoarthrosis, and relief of the symptoms associated therewith.
A similar to lesser dose rate could be administered on a daily basis as a prophylactic. A preferred unit dose is from about
0.001 to about 50, such as 0.001-20, mg/kg/day. The total daily dose would be about 0.1 to about 5000 mg/day, such
as 0.5-500 mg/day. For example, the unit dose may be administered by compounding into tablets or capsules, each
containing from 0.01-500 mg of 3-β-D-galactopyranosyloxy-2-(octadeca-9Z,12Z,15Z-trienoyloxy)propanyl octadeca-9Z,
12Z,15Z-trienoate, the user taking from one to four capsules per day.
[0049] Although the focus of the invention discussed above is for human therapy, it is also contemplated to use the
anti-inflammatory agent in the preparation of a medicament for the treatment or prophylaxis of non-human mammals,
including domestic and farm animals, having an inflammatory condition caused for example by arthritis. The skilled
artisan would readily ascertain the mode and method of therapy based on the animal to be treated. For example, the
composition can be incorporated into the animal’s water source or feed, or it can be administered as other medicaments,
in the form of a tablet, capsule, liquid, emulsion, or the like.
[0050] As it is often required for regulatory reasons to standardise plant extracts or materials used as natural medicine
for humans, a further aspect of the present invention relates to a method for standardising a natural medicine product
with respect to one compound of the formula 1: 
wherein R and R’ independently are selected from hydrogen, C10-24-alkyl, and C10-24-acyl, said alkyl and acyl groups
having 0 to 5 unsaturated bonds, and R1, R2, R3 and R4 independently are selected from hydrogen and glycoside
moieties, with the proviso that not both of R and R’ are hydrogen,
as an active ingredient, said natural medicine product being intended for the treatment, alleviation or prophylaxis of
inflammatory conditions in a mammal, the method comprising:
(a) providing a batch of a plant extract or material containing the compound of formula I;
(b) determining the concentration of the compound of formula I in said batch;
(c) preparing the natural medicine product in the form of unit dose forms each comprising a predetermined amount
of the active ingredient, wherein the predetermined amount of the active ingredient is provided by a quantity of said
batch, said quantity being determined as the predetermined amount of the active ingredient divided by the concen-
tration of the active ingredient in said batch. The compound of formula I is preferably 3-β-D-galactopyranosyloxy-
2-(octadeca-9Z,12Z,15Z-trienoyloxy)propanyl octadeca-9Z,12Z,15Z-trienoate. This aspect is further illustrated in
Example 4.
[0051] While preferred embodiments of the present invention have been shown and described, it will be understood
by those skilled in the art that various changes or modifications can be made without varying from the spirit and scope
of the present invention, and the invention is not limited to the examples given.
EXAMPLE 1
[0052] This example illustrates how the active principle of rose-hip was isolated from extracts of rose-hips by activity
guided fractionation and the methods used for the identification of the active compound (GOPO). This example also
illustrates a method for the quantification of the active compound by analytical HPLC in for example hip-rose extracts.
Activity guided fractionation and identification of the active compound
[0053] The active compound in the dog rose fruits was determined by activity guided fractionation. Thus, 1000 grams
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of dried and milled fruits were sequentially extracted with hexane, dichloromethane, methanol and water, and the extracts
evaporated. The resulting residues were tested for inhibition of chemotaxis of human peripheral blood neutrophils in
vitro. From these results it was determined that the active component(s) was present in the dichloromethane extract
(Figure 1). This extract was separated into clusters of components by silica gel chromatography using a gradient eluent
of dichloromethane and methanol (starting with dichloromethane only and ending with methanol only) and the individual
fractions tested for inhibition of chemotaxis of human peripheral blood neutrophils in vitro. From these results, it was
concluded that the activity in these assays was mainly if not exclusively confined to a single compound. This compound
was purified by preparative HPLC and the structure identified by 1H-, 13C-, NOESY-, COSY-, and HETCOR-NMR ex-
periments to be 3-β-D-galactopyranosyloxy-2-(octadeca-9Z,12Z,15Z-trienoyloxy)propanyl octadeca-9Z,12Z,
15Z-trienoate (GOPO). The chemical structure was further confirmed by basic hydrolysis in methanol (methanolysis)
and acidic hydrolysis. Basic hydrolysis afforded methyl linolenate as the only methyl ester as shown by GC-MS analysis,
whereas acidic hydrolysis afforded D-galactose and glycerol as shown by analytical HPLC analysis. 
[0054] Tables 1 and 2 shows the NMR data for the isolated active compound (GOPO). The NMR data (CD3OD) of
GOPO are fully in accordance with those found by Wegner et al. in Wegner, C., M. Hamburger, O. Kunert, and E.
Haslinger. 2000. Tensioactive Compounds from the Aquatic Plant Ranunculus fluitans L. (Ranunculaceae). Helv. Chim.
Acta 83: 1454-1464 (Ref. 1).
TABLE 1.13C-NMR spectral data (75 MHz, CDCl3 or CD3OD, δ-values in ppm) for GOPO.
Assignments Multiplicity* δc(CDCl3) δc(CD3OD) δc(CD3OD) Data from Ref. 1
C-1 d 104.3 106.3 105.4
C-2 d 71.6 73.3 72.4
C-3 d 73.7 75.7 74.9
C-4 d 69.5 71.1 70.2
C-5 d 74.8 77.7 76.8
C-6 t 62.4 63.3 62.5
C-1’ t 63.1 64.9 64.0
C-2’ d 70.4 72.7 71.8
C-3’ t 68.4 69.6 68.7
C-1", C-1"’ s 174.1, 173.7 176.1, 175.8 175.0, 174.7
C-2", C-2’" t 34.5, 34.3 36.0, 35.8 35.1, 35.0
C-3", C-3"’ t 25.1a 26.8a 26.6a
C-4", C-4’" t 29.8b 31.6b 30.8b
C-5", C-5"’ t 29.5b 31.2b 30.4b
C-6", C-6"’ t 29.4b 31.1b 30.3b
C-7", C-7"’ t 29.3b 31.0b 30.2b
C-8", C-8"’ t 27.4 29.0 28.2
C-9", C-9"’ d 132.2c 133.8c 132.7c
C-10", C-10"’ d 130.4c 132.1c 131.1c
C-11", C-11"’ t 25.9a 27.4a 26.4a
C-12", C-12"’ d 128.6c 130.2c 129.2c
C-13", C-13"’ d 128.5c 130.2c 129.2c
C-14", C-14"’ t 25.8a 27.3a 26.0
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Materials and Method
[0055] 5 Dried and milled fruits of dog rose (Rosa canina L.) were obtained from Hyben Vital International ApS (Tul-
lebølle, Denmark). HPLC-grade hexane, methanol (CH3OH), acetonitrile (CH3CN), dichloromethane (CH2Cl2), and tet-
rahydrofuran (THF) were obtained from Merck (Darmstadt, Germany). Silica gel 60 (0.063 - 0.200 mm) and anaiyticai
(0.1  mm) silica gel 60 F254 plates (TLC plates) were also obtained from Merck. Analytical TLC plates were developed
using 10 % H2SO4 in CH3OH followed by heating.
Extraction procedure
[0056] Dog rose powder (1000 g) were submerged in hexane (2 L) for 24 hours, filtered and the powder washed with
hexane (2 3 500 mL). The combined hexane solutions were evaporated to dryness under reduced pressure. The powder
was then submerged in CH2Cl2 (2 L) for 24 hours, filtered and the residual powder washed with CH2Cl2 (2 3 500 mL).
The combined CH2Cl2 solutions were evaporated to dryness under reduced pressure. The powder was then submerged
in CH3OH (2 L) for 24 hours, filtered and the powder washed with CH3OH (2 3 500 mL). The combined CH3OH solutions
were evaporated to dryness under reduced pressure. Finally the powder was submerged in water (2 L) for 24 hours,
filtered and the powder washed with water (2 3 500 mL). The combined water solutions were evaporated to dryness
(continued)
Assignments Multiplicity* δc(CDCl3) δc(CD3OD) δc(CD3OD) Data from Ref. 1
C-15", C-15"’ d 128.0c 129.9c 128.9c
C-16", C-16"’ d 127.3c 129.2c 128.3c
C-17", C-17"’ t 20.8 22.3 21.5
C-18", C-18"’ q 14.5 15.5 14.7
*Multiplicity determined by DEPT and HETCOR-NMR experiments. Abbreviations for multiplicity: s =
singlet, d = doublet, t = triplet, q = quartet. a, b, c In the same column: These assignments may be
interchanged.
TABLE 2 .1H-NMR spectral data (300 MHz, CD3OD, δ-values in ppm) for GOPO.
H δ H (multiplicity, J in Hz),CD3OD δ H (multiplicity, J in Hz), CD3OD (Ref. 1)
1 4.23 (d, 6.6) 4.23 (d, 7.3)
2 3.51 (dd, 6.6, 9.7) 3.52 (dd, 7.4, 9.8)
3 3.45 (dd, 2.1, 9.7) 3.45 (dd, 3.3, 10.3)
4 3.84 (dd, 0.5, 2.1) 3.83 (dd, 1.0, 2.5)
5 3.48 (m) 3.48 (m)
6a 3.73 (dd, 6.6, 12.0) 3.71 (m)
6b 3.75 (dd, 4.4, 12.0) 3.76 (m)
1’a 4.22 (dd, 6.9, 12.0) 4.23 (dd, 7.3, 13.6)
1’b 4.43 (br d, 12.0) 4.44 (dd, 3.0, 12.1)
2’ 5.27 (m) 5.26 (m)
3’a 3.71 (dd, 5.4, 11.0) 3.70 (dd, 5.4, 11.2)
3’b 3.98 (dd, 5.4, 10.8) 3.97 (dd, 5.4, 10.9)
2",2"’ 2.32 (br t, 7.0) 2.32 (m)
3",3"’ 1.60 (m) 1.59 (m)
4"-7", 4"’-7"’ 1.35 (m) 1.32 (m)
8",17",8’",17’" 2.08 (m) 2.08 (m)
9",10",12",13",15",16" 5.35 (m) 5.33 (m)
9’",10’",12’",13"’,15’",16’"
11",14", 11"’, 14"’ 2.82 (br t, 6.8) 2.80 (m)
18", 18"’ 0.98 (t, 7,5) 0.97 (t, 7.5)
Abbreviations for multiplicity: d = doublet, dd = double doublet, m = multiplet, t = triplet. br = broad.
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under reduced pressure (Figure 1).
Chromatographic conditions
[0057] The residue from evaporation of the CH2Cl2 solutions were dissolved in 100 mL CH2Cl2 and the solution placed
on a silica gel column (500 3 40 mm i.d.) in hexane. The column was eluted with a stepwise gradient (1 L) of CH3OH
in CH2Cl2 (0, 1, 2, 5, 10, 20, and 100 % CH3OH). Each fraction (100 mL) was analyzed by analytical TLC and, if relevant,
evaporated to dryness under reduced pressure.
Preparative HPLC conditions
[0058] For preparative HPLC a Merck L-6200 intelligent pump and a Merck L-4200 UV-VIS detector were used.
Separations were performed at 35 °C on a Develosil ODS-HG-5 (RP-18, particle size 5 mm; 250 3 20 mm i.d., Nomura
Chemical Co., Japan) column protected with a guard cartridge (50 3 20 mm i.d.) packed with the same material as the
column, using the following gradient: 150 mL 25 % CH3CN(aq); 150 mL 50 % CH3CN(aq); 150 mL 60 % CH3CN(aq);
150 mL 70 % CH3CN(aq); 150 mL 80 % CH3CN(aq); 150 mL 90 % CH3CN(aq) and 300 mL 100 % CH3CN. Compounds
were detected at 203 nm. Flow rate: 5 mL min-1. Injection volume: 5 mL.
Analytical HPLC conditions
[0059] Analytical HPLC was performed on a SUMMIT/Dionex HPLC system equipped with a photodiode array detector
(wavelength range 195-700 nm). The purity of the isolated compounds were determined at 35 °C by reversed phase
analytical HPLC on a LiChrospher 100 RP-18 (particle size 5 mm; 244 3 4 mm i.d., Merck) column using the following
gradient: 0-10 min (100 % solvent B); 10-25 min (100-50 % solvent B, 0-50 % solvent A); 25-55 min (50-0 % solvent B,
50-100 % solvent A); 55-64 min (100 % solvent A); 64-74 min (100-80 % solvent A, 0-20 % solvent C); 74-85 min (80
% solvent A, 20 % solvent C); 85-95 min (80-100 % solvent A, 20-0 % solvent C); 95-105 min (100-0 % solvent A, 0-100
% solvent B); and 105-110 min (100 % solvent B). All changes in the gradient are linear programmed. Solvent A: 100%
CH3CN. Solvent B: 20 % CH3CN (aq). Solvent C: 100% THF. Compounds were detected at 203 nm. Data collection
time: 0-75 min. Flow rate: 1 mL min-1. Injection volume: 20 mL. Retention time for GOPO: approimately 54 min (Figure 2).
[0060] From these tests, it was determined that an extraction process for obtaining the galactolipid composition com-
prises the steps of obtaining a plant material such as rose-hips, drying and milling the plant material (rose-hips) to form
a powder, treating the powder with a first organic solvent, in which the galactolipid is insoluble, removing the organic
solvent to form a first residue, which is the galactolipid containing fraction. The use of an initial organic solvent extraction
step removes non-active constituents, to provide an increased concentration of the active extract fraction. The isolation
of the galactolipid involves the steps of treating the first residue with an organo/chloro solvent to extract the galactolipid
from the first residue, and removing the organo/chloro solvent to precipitate a galactolipid rich fraction.
[0061] It is also possible to obtain the galactolipid anti-inflammatory extract fraction by direct extraction of the rose-
hip powder using the organo/chloro solvent, and removing the organo/chloro solvent to precipitate a galactolipid rich
fraction.
EXAMPLE 2
[0062] This example illustrates the activity of the active component of Example 1 in different cell function assays.
Biological Data of GOPO
[0063] 20 mg/ml of GOPO prepared in dimethylsulfoxide (DMSO) was obtained from the process described above
and diluted in minimal essential medium (MEM), to final concentrations of 100 mg/ml, 50 mg/ml, 10 mg/ml, 1 mg/ml and
0.1 mg/ml for use in the cell function assays.
Polymorphonuclear Leukocytes
[0064] Polymorphonuclear leukocytes (PMNs) were isolated from the peripheral blood of healthy individuals in citrated
glass. The cells were separated by dextran density gradient and  lymphoprep separation. The purity of PMNs was greater
than 98% and the cell viability as determined by trypan blue dye exclusion was greater than 98%.
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Chemotaxis
[0065] Chemotaxis assay was performed using a modified Boyden chamber technique as described in Jensen, P.
and Kharazmi, A., Computer-assisted image analysis assay of human neutrophil chemotaxis in vitro. J. Immunol. Meth-
ods, 144, 43-48. 1991. The purified PMNs were pre-incubated with different dilutions of the extracted galactolipid for 30
min at 37°C. Following preincubation, the chemotaxis of the cells towards the chemotactic factor zymosan activated
serum (ZAS), which contains the biologically active chemoattractant C5a, were tested. The migrated cells were counted
by a computer-assisted image analysis system.
Chemiluminescence
[0066] Chemiluminescence assay was used as a measure of oxygen radical generation by activated PMNs. The
method was performed as described in Kharazmi, A., Høiby, N., Doring, G., and Valerius, N.H. Pseudomonas aeruginosa
exoproteases inhibit human neutrophil chemiluminescence. Infect. Immun. 44, 587, 1984. PMNs were pre-incubated
with different concentrations of the extracted galactolipid and then stimulated with opsonized zymosan. The oxidative
burst response of the activated cells was measured by a luminometer (1250-LKB Wallace).
Results
Chemotaxis
[0067] Table 3 shows the results of the activity of GOPO, (100 mg/ml and 50 mg/ml dilutions) on chemotaxis of human
peripheral blood polymorphonuclear leukocytes. The results are shown as the number of cells migrated and the percent
inhibition.
[0068] The same experiments as shown in Table 3 were repeated on a new batch of the active compound (GOPO).
Table 4 shows the results of the activity of GOPO, (100 mg/ml, 10 mg/ml, 1 mg/ml and 0.1 mg/ml dilutions) on chemotaxis
of human peripheral blood polymorphonuclear leukocytes. The results are shown as the number of cells migrated and
the percent inhibition.
[0069] Table 5. Shows the results of chemiluminescence of human peripheral blood polymorphonuclear leukocytes.
The results are shown as millivolts.
TABLE 3
Preparation Cells migrated Percent inhibition
GOPO (100 mg/ml) 8 86
GOPO (50 mg/ml) 5 92
DMSO control 59 0
TABLE 4
Preparation Cells migrated Percent inhibition
GOPO (100 mg/ml) 12 71
GOPO (10 mg/ml) 16 62
GOPO (1 mg/ml) 15 64
GOPO (0.1 mg/ml) 39 7
DMSO control 42 0
TABLE 5
Preparation Millivolts
GOPO (100 mg/ml) 339
GOPO (50 mg/ml) 520
DMSO control 664
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[0070] Table 6. Shows the results of cell viability. Cell viability was determined by a trypan blue dye exclusion method.
The cells were incubated with trypan blue. The dead cells will take up dye and appear blue under the microscope. The
results are show as percent viable cells.
Conclusions
[0071] As shown in Tables 3 and 4, the isolated compound (GOPO) at fairly low concentrations inhibited the migration
of human peripheral blood leukocytes towards the biologically active chemoattractant zymosan-activated serum, which
contains C5a.
[0072] As shown in Table 5, the isolated compound at fairly low concentrations inhibited the chemiluminescence of
human peripheral blood leukocytes. Chemiluminescence is a measure of oxidative burst response. This indicates that
the isolated compound exhibits anti-oxidant activity. As the actual tissue damage caused by inflammatory cells such as
PMN’s and monocytes/macrophages, through the release of proteolytic and hydrolytic enzymes as well as toxic reactive
oxygen radicals activated in the tissue and joints, the isolated compound should be a potent inhibitor of the oxidative
burst response of the human peripheral blood polymorphonuclear leukocytes, the most important and abundant inflam-
matory cells.
[0073] As shown in Table 6, the cells were viable at concentrations of the compound, which inhibited chemotaxis and
chemiluminescence, indicating that the inhibition of cell migration and oxidative burst is not related to toxicity. In other
words the active compound does not appear to be toxic at the tested concentrations.
EXAMPLE 3
[0074] This example illustrates the concentration (mg/kg) of the active component of Example 1 and 2 in commercial
hip-rose products.
[0075] Analysis of commercial products of dog rose for GOPO by analytical HPLC.
[0076] The analytical HPLC method described under the section ’Analytical HPLC conditions’ was validated with regard
to specificity, repeatability, intermediate precision, accuracy, linearity, range and robustness according to the ICH-
guidelines from the European Commission (Volume 3 A Guidelines; Medicinal products for human use; Quality and
biotechnology 1998 Edition) and was used to quantify GOPO in commercially available products of dog rose. In Table
7 the results from the analysis of 10 commercial dog rose products for GOPO is shown.
TABLE 6
Preparation Percent viability
GOPO (100 mg/ml) 99
GOPO (50 mg/ml) 100
DMSO control 100
TABLE 7
Commercial products GOPO (mg/kg dog rose product)
Hyben Vital 303.0
CP 1 75.8
CP 2 72.7
CP 3 62.1
CP 4 51.5
CP 5 40.9
CP 6 18.2
CP 7 15.2
CP 8 6.1
CP 9 6.1
CP = anonymous commercial product.
EP 1 453 844 B1
14
5
10
15
20
25
30
35
40
45
50
55
EXAMPLE 4
[0077] Use of the invention to prepare a standardised preparation.
[0078] According to the guidelines issued by the Danish Medicines Agency (Lægemiddelstyrelsen), a natural medicine
must be standardised, to contain a specified amount of a compound that is specific for the plant or animal substance
that it is prepared from. If a compound exists that is recognised as being responsible for the clinical effect of the drug,
it is defined as the active compound and must be used for the standardisation. If no active compound is known, the
producer can choose another characteristic compound as a marker compound for standardisation. Since the present
invention indicates that GOPO is the active compound in rose hip preparations that can alleviate pains due to arthritis,
it must be used for standardisation of any rose hip preparation that is registered as a natural medicine. Similar regulations
for the registration of standardised preparations of herbal products etc. exist in other countries.
[0079] If a product is standardised according to a compound such as GOPO, this means that each unit, e.g. tablet or
capsule, contains enough plant material to provide a defined amount of GOPO. If for example the unit dose is defined
as 0.1 mg, and the concentration in the  product is measured as 303 mg/kg, as described in Example 3, Table 7, each
unit made from this batch of material must contain 0.330 g of the crude product.
[0080] For practical reasons, rather than adjusting the amount of material used in each tablet or capsule, the crude
product is diluted by as much as is needed in order to obtain the desired concentration, and then a fixed amount of the
diluted product is used for each tablet or capsule. For example, to make capsules with a content of 500 mg material and
a unit dose of 0.1 mg GOPO from a batch of plant material containing 303 mg/kg, it must be diluted to a concentration
of 200 mg/kg. This can be accomplished by adding to the crude product an amount of chalk powder or other inert material
corresponding to 51.1% of the weight of the crude product. Then each capsule containing 500 mg diluted material will
also contain 0.1 mg GOPO, and thereby meet the requirements for a standardised product.
[0081] Alternatively, a high quality batch, e.g. one containing 303 mg/kg as above, can be mixed with a batch of lower
quality, e.g. one containing 75.8 mg/kg.
[0082] In this case the mixture would contain 54.6% of the high quality batch, providing 165.6 mg GOPO/kg, and
45.4% of the low quality batch, providing 34.4 mg/kg, in order to obtain in total the desired standardised concentration
of 200 mg/kg.
[0083] In any case, when the active compound is used for standardisation, the standard concentration must be chosen
so the final product contains a lower concentration of active compound than the best part of the raw materials. The
general principle outlined here is applicable to any of the types of compounds described in the text, and present in any
source material.
Claims
1. The use of a compound of the formula I: 
wherein R and R’ independently are selected from hydrogen, C10-24-alkyl, and C10-24-acyl, said alkyl and acyl groups
having 0 to 5 unsaturated bonds, and R1, R2, R3 and R4 independently are selected from hydrogen and glycoside
moieties; with the first proviso that not both of R and R’ are hydrogen, and with the second proviso that none of R
and R’ is eicosapentaenoyl, for the preparation of a medicament for the treatment, alleviation or prophylaxis of an
inflammatory condition selected from rheumatoid arthritis, inflammatory bowel diseases, reactive or osteo-arthritis
or other arthritides in a mammal.
2. The use according to claim 1, wherein R and R’ independently are selected from C10-24-alkyl and C10-24-acyl, e.g.
from C10-24-acyl, said alkyl and acyl groups having 0 to 5 unsaturated bonds.
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3. The use according to any of the preceding claims, wherein any alkyl and acyl groups have 0 to 4 unsaturated bonds,
such as 1-3 unsaturated bonds, e.g. 2 or 3 unsaturated bonds, in particular 3 unsaturated bonds.
4. The use according to any of the preceding claims, wherein any unsaturated bonds are double bonds.
5. The use according to any of the preceding claims, wherein R and R’ both are C16-20-acyl having 1 to 3 double bonds,
such as C18-acyl having 3 double bonds.
6. The use according to any of the preceding claims, wherein the compound has the formula II: 
wherein R, R’, R1, R2, R3 and R4 all are as defined in any of claims 1-5.
7. The use according to any of the preceding claims, wherein the compound is selected from β-D-galactopyranosyl
derivatives, α-D-galactopyranosyl derivatives, β-D-glucopyranosyl derivatives, and α-D-glucopyranosyl derivatives.
8. The use according to claim 1, wherein the compound is selected from 3-β-D-galactopyranosyloxy-2-(octadeca-9Z,
12Z,15Z-trienoyloxy)propanyl octadeca-9Z,12Z,15Z-trienoate, 3-β-D-glucopyranosyloxy-2-(octadeca-9Z,12Z,
15Z-trienoyloxy)propanyl octadeca-9Z,12Z,15Z-trienoate, 3-α-D-galactopyranosyloxy-2-(octadeca-9Z,12Z,15Z-
trienoyloxy)propanyl octadeca-9Z,12Z,15Z-trienoate, and 3-α-D-glucopyranosyloxy-2-(octadeca-9Z,12Z,
15Z-trienoyloxy)propanyl octadeca-9Z,12Z,15Z-trienoate.
9. The use according to any of the preceding claims, wherein the medicament is adapted for oral, buccal, parenteral,
topical, rectal, transdermal or intranasal administration.
10. The use according to any of the preceding claims, wherein the medicament is in the form of a daily dose form
applicable for administration of about 0.005-50 mg/kg body weight per day, in unitary or multiple doses.
11. The use according to any of the preceding claims, wherein the inflammatory condition is arthritis.
12. The use according to any of the preceding claims, wherein the inflammatory condition is osteoarthrosis.
13. The use according to any of the preceding claims, wherein the medicament comprises one or more compounds of
the above formula in a total concentration of 0.1-50% based on the total weight of the medicament.
14. The use according to any of the preceding claims, wherein the medicament further comprises an anti-oxidant.
15. A pharmaceutical composition comprising one or more compounds as defined in any of the claims 1-8, an antioxidant,
and a pharmaceutically acceptable carrier.
16. A composition according to claim 15, wherein the compound is selected from β-D-galactopyranosyl derivatives, α-
D-galactopyranosyl derivatives, β-D-glucopyranosyl derivatives, and α-D-glucopyranosyl derivatives
17. A composition according to any one of claims 15 or 16, wherein the compound is selected from 3-β-D-galactopyran-
osyloxy-2-(octadeca-9Z,12Z,15Z-trienoyloxy)propanyl octadeca-9Z,12Z,15Z-trienoate, 3-β-D-glucopyranosyloxy-
2-(octadeca-9Z,12Z,15Z-trienoyloxy)propanyl octadeca-9Z,12Z,15Z-trienoate, 3-α-D-galactopyranosyloxy-2-(octa-
deca-9Z,12Z,15Z-trienoyioxy)propanyl octadeca-9Z,12Z,15Z-trienoate, and 3-α-D-glucopyranosyloxy-2-(octade-
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ca-9Z,12Z,15Z-trienoyloxy)propanyl octadeca-9Z,12Z,15Z-trienoate.
18. A composition according to any one of claims 15-17, wherein the one or more compound(s) constitutes 0.1-50% by
weight.
19. A standardised product, based on rose hip material comprising a predetermined amount in a unit dose form in the
range of 0.01-500 mg of an active ingredient of the formula I: 
wherein R and R’ independently are selected from hydrogen, C10-24-alkyl, and C10-24-acyl, said alkyl and acyl groups
having 0 to 5 unsaturated bonds, and R1, R2, R3 and R4 independently are selected from hydrogen and glycoside
moieties, with the proviso that not both of R and R’ are hydrogen.
20. The product according to claim 19, wherein the active ingredient is 3-β-D-galactopyranosyloxy-2-(octadeca-9Z,12Z,
15Z-trienoyloxy)propanyl octadeca-9Z,12Z,15Z-trienoate.
21. A product according to any one of claims 19-20, wherein the product is prepared in the form of unit dose forms each
comprising a predetermined amount of the active ingredient, wherein the predetermined amount of the active in-
gredient is provided by a quantity of said batch, said quantity being determined as the predetermined amount of the
active ingredient divided by the concentration of the active ingredient in said batch.
22. A product according to any one of claims 19-21, wherein the active ingredient is provided in a predetermined unit
dose forms in the range of 0.001-50 mg/kg body weight.
23. A product according to any one of claims 19-22, wherein the product is a natural medicine product.
Patentansprüche
1. Verwendung einer Verbindung der Formel I: 
wobei R und R’ unabhängig voneinander ausgewählt sind aus Wasserstoff, C10-24-Alkyl und C10-24-Acyl, wobei die
Alkyl- und Acylgruppen 0 bis 5 ungesättigte Bindungen aufweisen, und R1, R2, R3 und R4 unabhängig voneinander
ausgewählt sind aus Wasserstoff und Glycosidanteilen; mit der ersten Maßgabe, dass R und R’ nicht gleichzeitig
Wasserstoff sind, und mit der zweiten Maßgabe, dass weder R noch R’ Eicosapentaenoyl ist, zur Herstellung eines
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Arzneimittels zur Behandlung, Linderung oder Prophylaxe eines entzündlichen Zustands, ausgewählt aus der Grup-
pe, bestehen aus rheumatoider Arthritis, entzündlichen Darmkrankheiten, reaktiver oder Osteoarthritis oder anderen
Arthritiserkrankungen bei einem Säugetier.
2. Verwendung nach Anspruch 1, wobei R und R’ unabhängig voneinander ausgewählt sind aus C10-24-Alkyl und
C10-24-Acyl, z. B. aus C10-24-Acyl, wobei die Alkyl- und Acylgruppen 0 bis 5 ungesättigte Bindungen aufweisen.
3. Verwendung nach einem der vorhergehenden Ansprüche, wobei jede Alkyl- und Acylgruppe 0 bis 4 ungesättigte
Bindungen aufweist, wie 1-3 ungesättigte Bindungen, beispielsweise 2 oder 3 ungesättigte Bindungen, insbesondere
3 ungesättigte Bindungen.
4. Verwendung nach einem der vorhergehenden Ansprüche, wobei jede ungesättigte Bindung eine Doppelbindung ist.
5. Verwendung nach einem der vorhergehenden Ansprüche, wobei R und R’ beide C16-20-Acyl mit 1 bis 3 Doppelbin-
dungen sind, wie C18-Acyl mit 3 Doppelbindungen.
6. Verwendung nach einem der vorhergehenden Ansprüche, wobei die Verbindung die Formel II aufweist: 
wobei R, R’, R1, R2, R3 und R4 alle wie in einem der vorstehenden Ansprüche 1-5 definiert sind.
7. Verwendung nach einem der vorhergehenden Ansprüche, wobei die Verbindung ausgewählt ist aus β-D-Galacto-
pyranosylderivaten, α-D-Galactopyranosylderivaten, β-D-Glucopyranosylderivaten und α-D-Glucopyranosylderiva-
ten.
8. Verwendung nach einem der vorhergehenden Ansprüche, wobei die Verbindung ausgewählt ist aus 3-β-D-Galac-
topyranosyloxy-2-(octadeca-9Z,12Z,15Z-trienoyloxy)propanyloctadeca-9Z,12Z,15Z-trienoat, 3-β-D-Glucopyrano-
syloxy-2-(octadeca-9Z,12Z,15Z-trienoyloxy)propanyloctadeca-9Z,12Z,15Z-trienoat, 3-α-D-Galactopyranosyloxy-
2-(octadeca-9Z,12Z,15Z-trienoyloxy)propanyloctadeca-9Z,12Z,15Z-trienoat und 3-α-D-Glucopyranosyloxy-2-(oc-
tadeca-9Z,12Z,15Z-trienoyloxy)propanyloctadeca-9Z,12Z,15Z-trienoat.
9. Verwendung nach einem der vorhergehenden Ansprüche, wobei das Arzneimittel für die orale, bukkale, parenterale,
topische, rektale, transdermale oder intranasale Verabreichung angepasst ist.
10. Verwendung nach einem der vorhergehenden Ansprüche, wobei das Arzneimittel in Form einer Tagesdosisform
vorliegt, die für die Verabreichung von etwa 0,005 /mg/kg Körpergewicht pro Tag in einer oder mehreren Dosen
geeignet ist.
11. Verwendung nach einem der vorhergehenden Ansprüche, wobei der entzündliche Zustand Arthritis ist.
12. Verwendung nach einem der vorhergehenden Ansprüche, wobei der entzündliche Zustand Osteoarthritis ist.
13. Verwendung nach einem der vorhergehenden Ansprüche, wobei das Arzneimittel eine oder mehrere Verbindungen
der vorstehenden Formel in einer Gesamtkonzentration von 0,1 bis 50 % bezogen auf das Gesamtgewicht des
Arzneimittels umfasst.
14. Verwendung nach einem der vorhergehenden Ansprüche, wobei das Arzneimittel weiterhin ein Antioxidationsmittel
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umfasst.
15. Pharmazeutische Zusammensetzung, umfassend eine oder mehrere Verbindungen wie in einem der Ansprüche
1-8 definiert, ein Antioxidationsmittel und einen pharmazeutisch verträglichen Träger.
16. Zusammensetzung nach Anspruch 15, wobei die Verbindung ausgewählt ist aus β-D-Galactopyranosyloxyderivaten,
α-D-Galactopyranosyloxyderivaten, β-D-Glucopyranosylderivaten und α-D-Glucopyranosylderivaten.
17. Zusammensetzung nach einem der Ansprüche 15 oder 16, wobei die Verbindung ausgewählt ist aus 3-β-D-Galac-
topyranosyloxy-2-(octadeca-9Z,12Z,15Z-trienoyloxy)propanyloctadeca-9Z,12Z,15Z-trienoat, 3-β-D-Glucopyrano-
syloxy-2-(octadeca-9Z,12Z,15Z-trienoyloxy)propanyloctadeca-9Z,12Z,15Z-trienoat, 3-α-D-Galactopyranosyloxy-
2-(octadeca-9Z,12Z,15Z-trienoyloxy)propanyloctadeca-9Z,12Z,15Z-trienoat und 3-α-D-Glucopyranosyloxy-2-(oc-
tadeca-9Z,12Z,15Z-trienoyloxy)propanyloctadeca-9Z,12Z,15Z-trienoat.
18. Zusammensetzung nach einem der Ansprüche 15-17, wobei die eine oder mehreren Verbindungen 0,1-50 Gew.-
% darstellen.
19. Standardisiertes Produkt auf der Grundlage von Hagebuttenmaterial, umfassend eine vorbestimmte Menge Ein-
heitsdosisform im Bereich von 0,01-500 mg eines Wirkstoffs der Formel I: 
wobei R und R’ unabhängig voneinander ausgewählt sind aus Wasserstoff, C10-24-Alkyl und C10-24-Acyl, wobei die
Alkyl- und Acylgruppen 0 bis 5 ungesättigte Bindungen aufweisen, und R1, R2, R3 und R4 unabhängig voneinander
ausgewählt sind aus Wasserstoff und Glycosidanteilen, mit der Maßgabe, dass R und R’ nicht gleichzeitig Wasser-
stoff sind.
20. Produkt nach Anspruch 19, wobei der Wirkstoff 3-β-D-Galactopyranosyloxy-2-(octadeca-9Z,12Z,15Z-trienoyloxy)
propanyloctadeca-9Z,12Z,15Z-trienoat ist.
21. Produkt nach einem der Ansprüche 19-20, wobei das Produkt in Form von Einheitsdosisformen hergestellt wird,
die jeweils eine vorbestimmte Menge des Wirkstoffs umfassen, wobei die vorbestimmte Menge des Wirkstoffs durch
eine Menge der Charge  bereitgestellt wird, wobei die Menge als die vorbestimmte Menge des Wirkstoffs dividiert
mit der Konzentration des Wirkstoffs in jeder Charge ermittelt wird.
22. Produkt nach einem der Ansprüche 19-21, wobei der Wirkstoff in einer vorbestimmten Einheitsdosisform im Bereich
von 0,001-50 mg/kg Körpergewicht bereitgestellt wird.
23. Produkt nach einem der Ansprüche 19-22, wobei das Produkt ein Naturheilmittelprodukt ist.
Revendications
1. L’utilisation d’un composé de formule I : 
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dans laquelle R et R’ sont choisis indépendamment parmi un hydrogène, un C10-24-alkyle et un C10-24-acyle, lesdits
groupes alkyle et acyle possédant 0 à 5 liaisons insaturées, et R1, R2, R3 et R4 sont choisis indépendamment parmi
des fractions hydrogène et glycoside ; à la première condition que R et R’ ne soient pas tous deux un hydrogène,
et à la seconde condition qu’aucun de R et R’ ne soit un eicosapentaénoyle, pour la préparation d’un médicament
destiné au traitement, au soulagement ou à la prophylaxie d’une maladie inflammatoire choisie parmi la polyarthrite
rhumatoïde, les maladies inflammatoires de l’intestin, l’arthrite réactionnelle ou l’ostéo-arthrite ou d’autres arthrites
chez un mammifère.
2. L’utilisation selon la revendication 1, dans laquelle R et R’ sont choisis indépendamment parmi un C10-24-alkyle et
un C10-24-acyle, par exemple un C10-24-acyle, lesdits groupes alkyle et acyle possédant 0 à 5 liaisons insaturées.
3. L’utilisation selon l’une quelconque des revendications précédentes, dans laquelle tous les groupes alkyle et acyle
possèdent 0 à 4 liaisons insaturées, telles que 1 à 3 liaisons insaturées, par exemple 2 ou 3 liaisons insaturées, en
particulier 3 liaisons insaturées.
4. L’utilisation selon l’une quelconque des revendications précédentes, dans laquelle toutes les liaisons insaturées
sont des doubles liaisons.
5. L’utilisation selon l’une quelconque des revendications précédentes, dans laquelle R et R’ sont tous deux un
C16-20-acyle possédant 1 à 3 doubles liaisons, tel qu’un C18-acyle possédant 3 doubles liaisons.
6. L’utilisation selon l’une quelconque des revendications précédentes, dans laquelle le composé possède la formule II : 
dans laquelle R, R’, R1, R2, R3 et R4 sont tous tels que définis dans l’une quelconque des revendications 1 à 5.
7. L’utilisation selon l’une quelconque des revendications précédentes, dans laquelle le composé est choisi parmi des
dérivés du β-D-galactopyranosyle, des dérivés du α-D-galactopyranosyle, des dérivés du β-D-glucopyranosyle et
des dérivés du α-D-glucopyranosyle.
8. L’utilisation selon la revendication 1, dans laquelle le composé est choisi parmi le 3-β-D-galactopyranosyloxy-
2-(octadéca-9Z,12Z,15Z-triénoyloxy)propanyl octadéca-9Z,12Z,15Z-triénoate, le 3-β-D-glucopyranosyloxy-2-(octa-
déca-9Z,12Z,15Z-triénoyloxy)propanyl octadéca-9Z,12Z,15Z-triénoate, le 3-α-D-galactopyranosyloxy-2-(octadéca-
9Z,12Z,15Z-triénoyloxy)propanyl octadéca-9Z,12Z,15Z-triénoate et le 3-α-D-glucopyranosyloxy-2-(octadéca-9Z,
12Z,15Z-triénoyloxy)propanyl octadéca-9Z,12Z,15Z-triénoate.
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9. L’utilisation selon l’une quelconque des revendications précédentes, dans laquelle le médicament est adapté pour
une administration orale, buccale, parentérale, topique, rectale, transdermique ou intranasale.
10. L’utilisation selon l’une quelconque des revendications précédentes, dans laquelle le médicament se présente sous
la forme d’une dose quotidienne utilisable pour l’administration d’environ 0,005 à 50 mg/kg de poids corporel par
jour, par dose unitaire ou doses multiples.
11. L’utilisation selon l’une quelconque des revendications précédentes, dans laquelle la maladie inflammatoire est
l’arthrite.
12. L’utilisation selon l’une quelconque des revendications précédentes, dans laquelle la maladie inflammatoire est
l’arthrose.
13. L’utilisation selon l’une quelconque des revendications précédentes, dans laquelle le médicament comprend un ou
plusieurs composés de formule ci-dessus dans une concentration totale de 0,1 à 50 % sur la base du poids total
du médicament.
14. L’utilisation selon l’une quelconque des revendications précédentes, dans laquelle le médicament comprend éga-
lement un antioxydant.
15. Composition pharmaceutique comprenant un ou plusieurs composés tels que définis dans l’une quelconque des
revendications 1 à 8, un antioxydant et un véhicule pharmaceutiquement acceptable.
16. Composition selon la revendication 15, dans laquelle le composé est choisi parmi des dérivés du β-D-galactopyra-
nosyloxyle, des dérivés du α-D-galactopyranosyle, des dérivés du β-D-glucopyranosyle et des dérivés du α-D-
glucopyranosyle.
17. Composition selon l’une quelconque des revendications 15 ou 16, dans laquelle le composé est choisi parmi le 3-
β-D-galactopyranosyloxy-2-(octadéca-9Z,12Z,15Z-triénoyloxy)propanyl octadéca-9Z,12Z,15Z-triénoate, le 3-β-D-
glucopyranosyloxy-2-(octadéca-9Z,12Z,15Z-triénoyloxy)propanyl octadéca-9Z,12Z,15Z-triénoate, le 3-α-D-galac-
topyranosyloxy-2-(octadéca-9Z,12Z,15Z-triénoyloxy)propanyl octadéca-9Z,12Z,15Z-triénoate et le 3-α-D-glucopy-
ranosyloxy-2-(octadéca-9Z,12Z,15Z-triénoyloxy)propanyl octadéca-9Z,12Z,15Z-triénoate.
18. Composition selon l’une quelconque des revendications 15 à 17, dans laquelle les un ou plusieurs composés
représentent 0,1 à 50 % en poids.
19. Produit standardisé à base de matière issue du cynorrhodon comprenant une quantité prédéterminée, sous forme
de dose unitaire allant de 0,01 à 500 mg, d’un ingrédient actif de formule I : 
dans laquelle R et R’ sont choisis indépendamment parmi un hydrogène, un C10-24-alkyle et un C10-24-acyle, lesdits
groupes alkyle et acyle possédant 0 à 5 liaisons insaturées, et R1, R2, R3 et R4 sont choisis indépendamment parmi
des fractions hydrogène et glycoside, à la condition que R et R’ ne soient pas tous deux un hydrogène.
20. Le produit selon la revendication 19, dans lequel l’ingrédient actif est le 3-β-D-galactopyranosyloxy-2-(octadéca-
9Z,12Z,15Z-triénoyloxy)propanyl octadéca-9Z,12Z,15Z-triénoate.
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21. Produit selon l’une quelconque des revendications 19 à 20, dans lequel le produit est préparé sous la forme de
doses unitaires comprenant chacune une quantité prédéterminée de l’ingrédient actif, dans lequel la quantité pré-
déterminée de l’ingrédient actif est apportée par une quantité dudit lot, ladite quantité étant déterminée comme la
quantité prédéterminée de l’ingrédient actif divisée par la concentration de l’ingrédient actif dans ledit lot.
22. Produit selon l’une quelconque des revendications 19 à 21, dans lequel l’ingrédient actif est apporté sous la forme
d’une dose unitaire prédéterminée allant de 0,001 à 50 mg/kg de poids corporel.
23. Produit selon l’une quelconque des revendications 19 à 22, dans lequel le produit est un produit médicamenteux
naturel.
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